Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer.
Matsubara N, Mukai H, Itoh K, Nagai S.
Oncology. 2011;81(5-6):345-52. Epub 2012 Jan 13.
Related citations
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB.
Oncology. 2011;81(5-6):298-305. Epub 2011 Dec 8.
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Vici P, Giotta F, Di Lauro L, Sergi D, Vizza E, Mariani L, Latorre A, Pizzuti L, D'Amico C, Giannarelli D, Colucci G.
Oncology. 2011;81(3-4):230-6. Epub 2011 Nov 17.
Does surgery for breast cancer induce angiogenesis and thus promote metastasis?
Park Y, Kitahara T, Takagi R, Kato R.
Oncology. 2011;81(3-4):199-205. Epub 2011 Nov 8. Review.
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers.
Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, von Moos R, Müller A, von Rohr L, Widmer I, Thürlimann B.
Oncology. 2011;81(3-4):160-6. Epub 2011 Oct 28.
Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
Kilic N, Myrick ME, Schmid SM, Gueth U.
Oncology. 2011;81(3-4):151-7. Epub 2011 Oct 25.
A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
Ferrero JM, Largillier R, Michel C, Amiot V, Milano G, Hébert C, Mari V, Courdi A, Figl A, Follana P, Barrière J, Chamorey E.
Oncology. 2011;81(2):73-8. Epub 2011 Sep 30.
Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations.
Kong JH, Park YH, Kim JA, Kim JH, Yun J, Sun JM, Won YW, Lee S, Kim ST, Cho EY, Ahn JS, Im YH.
Oncology. 2011;81(1):55-62. Epub 2011 Sep 16.
Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E.
Oncology. 2011;81(1):30-8. Epub 2011 Sep 9.
Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients.
Vaidya R, Sood R, Karlin N, Jatoi A.
Oncology. 2011;81(1):9-11. Epub 2011 Sep 2.
Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.
Oncology. 2011;80(5-6):341-9. Epub 2011 Jul 26.
Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP, Blackwell KL.
Oncology. 2011;80(5-6):314-25. Epub 2011 Jul 19. Review.
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
Oncology. 2011;80(3-4):269-77. Epub 2011 Jul 7.
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C, Boisseau M, Kaphan R, Dramais D, Oprea C, Ferri-Dessens RM, Guastalla JP, Perol D.
Oncology. 2011;80(3-4):262-8. Epub 2011 Jul 6.
The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.
Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D.
Oncology. 2011;80(3-4):225-31. Epub 2011 Jul 5.
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
Oncology. 2010;79(5-6):376-81. Epub 2011 Mar 24.
Local recurrence after breast cancer affects specific survival differently according to patient age.
Courdi A, Doyen J, Gal J, Chamorey E.
Oncology. 2010;79(5-6):349-54. Epub 2011 Mar 23.
Is capecitabine efficacious in triple negative metastatic breast cancer?
Kotsori AA, Dolly S, Sheri A, Parton M, Shaunak N, Ashley S, Walsh G, Johnston S, Smith IE.
Oncology. 2010;79(5-6):331-6. Epub 2011 Mar 23.
Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW.
Oncology. 2010;79(5-6):324-30. Epub 2011 Mar 23.
Error occurred: cannot get document summary
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on